Editorials

Measuring Flares in Rheumatoid Arthritis. (Why) Do We Need Validated Criteria?
A. van der Maas, A.A. den Broeder .................................. 189

Belimumab in Systemic Lupus Erythematosus — What Can Be Learned from Longterm Observational Studies?
A.A. Bengtsson ................................................................. 192

Articles

Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses

Update of Strategies to Translate Evidence from Cochrane Musculoskeletal Group Systematic Reviews for Use by Various Audiences

Continued Benefit of Tocilizumab Plus DMARD Therapy in Patients with RA and Inadequate Clinical Responses by Week 8 of Treatment

Flares in RA: Frequency and Management. A Report from the BRASS Registry
V.P. Bykerk, N. Shadick, M. Frits, et al .................................... 227

Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients with Early RA: a Posthoc Analysis of the PREMIER Study
E.C. Keystone, B. Harauqi, B. Guérette, N. Mozaffarian, S. Liu, A. Kavanoos .................................. 235

Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience
O. Elkayam, N. Jines, Z. Dranitzki, et al .................................. 244

Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in RA Independently of Traditional Cardiovascular Risk Factors
J. Avouac, C. Meune, C. Chenevier-Gobeaux, et al ...................................................... 248

Free online via JRheum Full Release option

Health Literacy Predicts Discrepancies Between Traditional Written Patient Assessments and Verbally Administered Assessments in RA
J.M. Hirsh, L.A. Davis, I. Quinzanos, A. Keniston, L. Caplan ................................................. 256

Number of Ruptured Tendons and Surgical Delay as Prognostic Factors for the Surgical Repair of Extensor Tendon Ruptures in the Rheumatoid Wrist
Y. Sakuma, K. Ochi, T. Iwamoto, et al ............................................. 265

Antihomocitrullinated Fibrinogen Antibodies Are Specific to RA and Frequently Bind Citrullinated Proteins/peptides
M. Scinocca, D.A. Bell, M. Racapé, et al ............................................. 270

Serum Cytokine Profile of Unaffected First-degree Relatives of Patients with RA
L. Barra, K. Summers, D. Bell, E. Cairns ............................................. 280

Safety of Etanercept and MTX in Patients with RA and Hepatitis C Virus Infection: A Multicenter Randomized Clinical Trial
F. Iannone, G. La Montagna, G. Bagnato, E. Gremese, A.R. Giardina, G. Lapadula .................................. 286

A Clinical, Pathological, and Genetic Characterization of MTX-associated Lymphoproliferative Disorders
N. Yamakawa, M. Fujimoto, D. Kawabata, et al ............................................. 293

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with SLE
E.M. Ginzler, D.J. Wallace, J.T. Merrill, et al, and the LBSL02/99 Study Group ............................................. 300

Peripheral Arterial Disease in SLE: Prevalence and Risk Factors

Evidence for Genetic Association of CARD9 and SNAPC4 with Ankylosing Spondylitis in a Chinese Han Population
X. Ma, Y. Liu, H. Zhang, et al ............................................. 318

Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan
S. Furuta, A.N. Chaudhry, Y. Hamano, et al ............................................. 325

Contents continued opposite inside back cover . . .